The understanding of neurodegenerative diseases, traditionally considered to be well-
defined entities with distinguishable clinical phenotypes, has undergone a major shift over …

The diagnosis of neurodegenerative diseases within neurology and psychiatry are
hampered by the difficulty in getting biopsies and thereby validating the diagnosis by …

The ideal biomarker needs to be easy to quantify and measure, reproducible, not subject to
wide variation in the general population and unaffected by co-morbid factors. For evaluation …

Biomarkers are very important indicators of normal and abnormal biological processes.
Specific changes in pathologies, biochemistries and genetics can give us comprehensive …

This special issue of Progress in Neurobiology entitled “Biomarkers for Neurodegenerative
Disorders” is a biomarker tour de force as a result of the heroic efforts of the experts in …

Biomarkers for neurodegenerative disorders are essential to facilitate disease diagnosis,
ideally at early stages, monitor disease progression, and assess response to existing and …

Neurodegenerative disorders are characterized by neuronal impairment that eventually
leads to neuronal death. In spite of the brain's known capacity for regeneration, lost neurons …

Neurodegenerative diseases are characterised by selective dysfunction and progressive
loss of synapses and neurons associated with pathologically altered proteins that deposit …

The technology, experimental approaches, and bioinformatics that support proteomic
research are evolving rapidly. The application of these new capabilities to the study of …

The identification of clinically relevant biomarkers for neurological diseases poses unique
challenges. These include an historical lack of availability of relevant tissues from the site of …